DE-THE-LYCRA-COMPANY
The LYCRA Company, a global leader in developing innovative fiber and technology solutions for the apparel and personal care industries, today announced wins related to its ongoing global efforts to protect its intellectual property (IP), including patents and trademarks, from infringement worldwide.
This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20211007005014/en/
The LYCRA Company recently initiated several infringement suits related to its dual core and multi-core patents for denim against third parties in China. These third parties were selling fibers and goods The LYCRA Company deemed to infringe on LYCRA® brand patents.
The Chinese National Intellectual Property Administration (CNIPA) has recently issued a formal decision in support of The LYCRA Company patents for two invalidity challenges. Subsequently, the Jiangsu Authority has informed The LYCRA Company that its patent has been upheld in both these cases.
“We are pleased with the outcome of these two cases with our patents being recognized and upheld by the Chinese authorities,” said Bridget Sciamanna, general counsel for The LYCRA Company. “Protecting our patents and trademarks is a key strategic priority for us in safeguarding the value of our global brands.”
Supporting Customers in Patent Infringement Actions
The LYCRA Company is proud to offer its customers and licensees unmatched support in patent challenges related to its products. In two recent cases, two licensees in Europe turned to The LYCRA Company for technical and legal assistance for their own patent litigation defenses related to the company’s dual core patents. This assistance helped bring about wins for the licensees against the challenger. The presiding court ruled the licensees were not infringing on the other company’s patent.
Fighting Trademark Infringement
As part of its ongoing effort to combat misuse and trademark infringement of its brands globally, The LYCRA Company actively searches online marketplaces to find listings for fabrics and garments that attempt to capitalize on its brands’ positive reputations to drive sales, despite its products not being used.
Only fabrics and garments that have been tested and certified by The LYCRA Company to confirm they contain its fibers and meet its brands’ performance standards are eligible to use its trademarks. Over the past 12 months, the company has successfully removed 2,400 website listings and over 800 social media profiles and posts that infringed on its trademarks.
One of the marketplace websites, a major ecommerce platform in China, immediately acted to correct or take down any listings by third party sellers with trademark infringement issues flagged by The LYCRA Company.
“When our brand names are used on inferior products, it not only damages the consumer’s perception of our brands, it can also diminish the value of a customer's investment in our products,” said Julien Born, ceo of The LYCRA Company. “We have significantly invested in innovation, branding, and marketing for decades, so we will always fight to protect and defend our intellectual property to the fullest extent of the law.”
In the past year, The LYCRA Company has been granted 52 patents globally for innovations across a range of technologies, including new polymers, fabric constructions, stretch and performance technologies, as well as processes for apparel and hygiene applications.
To learn more about LYCRA® brand trademarks, click here .
About The LYCRA Company
The LYCRA Company innovates and produces fiber and technology solutions for the apparel and personal care industries. Headquartered in Wilmington, Delaware, The LYCRA Company is recognized worldwide for its innovative products, technical expertise, sustainable solutions, and unmatched marketing support. The LYCRA Company owns leading consumer and trade brands: LYCRA®, LYCRA HyFit®, LYCRA® T400®, COOLMAX®, THERMOLITE®, ELASPAN®, SUPPLEX®, and TACTEL®. The LYCRA Company’s legacy stretches back to 1958 with the invention of the original spandex yarn, LYCRA® fiber. Today, The LYCRA Company focuses on adding value to its customers’ products by developing unique innovations designed to meet the consumer’s need for comfort and lasting performance. For more information, visit thelycracompany.com .
LYCRA® is a trademark of The LYCRA Company
View source version on businesswire.com: https://www.businesswire.com/news/home/20211007005014/en/
Link:
About Business Wire
Subscribe to releases from Business Wire
Subscribe to all the latest releases from Business Wire by registering your e-mail address below. You can unsubscribe at any time.
Latest releases from Business Wire
Meiji Seika Pharma Partners With MBC BioLabs to Strengthen Global Innovation in Drug Discovery19.12.2025 02:00:00 CET | Press release
Meiji Seika Pharma Co., Ltd. (Headquarters: Chuo-ku, Tokyo; President & CEO: Toshiaki Nagasato) today announced that it has entered into a partnership agreement with MBC BioLabs which is a private organization supporting the development of biotech startup companies in California’s San Francisco Bay Area. MBC BioLabs provides fully equipped research facilities and a supportive community that help biotech entrepreneurs accelerate from concept to company. By removing the burden of building and maintaining laboratory infrastructure, resident companies can focus early on research and development while efficiently advancing commercialization. Through this partnership, Meiji Seika Pharma will further advance its open-innovation initiatives and strengthen research and development in its priority therapeutic areas: infectious diseases, hematologic diseases, and immune-inflammatory diseases. By engaging with the entrepreneurs and startup community at MBC BioLabs, the company aims to discover inn
Enry's Island SpA Strengthens Its Leadership in Venture Capital with Explosive Growth and Redesigns the Future of VC Through Gaming19.12.2025 00:34:00 CET | Press release
Announcement of Enry’s Island AdVentures: the world’s first video game to learn how to launch and scale startups, focused on democratizing innovation for “Long Tail Users” Enry’s Island SpA (WBAG:EIOS), the world’s first publicly listed venture builder, announces a new era of growth, innovation, and the democratization of Venture Capital (VC). The company has delivered exceptional results, consolidating its position as an industry leader through a strategic positioning in the rapidly expanding gaming market. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20251218742236/en/ Record Growth and Performance Enry’s Island SpA has demonstrated an extraordinary growth trajectory and a strong financial and operational track record: Revenues: +250% year-over-year (YoY). Exit: $3.6M in exits realized via IPO. Portfolio: 1 IPO of a portfolio company completed in December 2024, with an additional 2 IPOs expected in 2026. The performance of
500 Global Expands Africa Presence; Selected to Advance Digital Morocco 2030 Strategy18.12.2025 21:37:00 CET | Press release
Part of the Digital Morocco 2030 strategy, 500 Global has been selected to support the Startup Venture Building (Startup VB) initiative. 500 Global, one of the world’s most active venture capital firms1, announced it has been selected to support the Ministry-led Startup VB initiative, a flagship program under the Digital Morocco 2030 strategy2. This announcement marks a significant milestone in 500 Global’s continued expansion across the African continent and its work collaborating with governments to strengthen national innovation ecosystems. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20251218363323/en/ Announcement of 500 Global's continued expansion across Africa and support of Digital Morocco 2030 Launched by the Ministry of Digital Transition and Administrative Reform (Ministry) and deployed by TAMWILCOM, the Startup VB initiative is a flagship program under the Digital Morocco 2030 strategy. Startup VB aims to streng
Neural Concept Closes $100M Funding Round Led by Growth Equity at Goldman Sachs Alternatives to Scale AI-Native Engineering18.12.2025 17:00:00 CET | Press release
New capital accelerates Neural Concept’s ability to deliver transformative technologies and enterprise-wide AI impact across advanced industrial workflows.Platform delivers CAD-native, physics-aware AI and deep reasoning for engineering, saving customers $50 million annually, reducing late-stage redesigns by 30-50% and accelerating time to market by up to two years.The company has generated a fourfold increase in enterprise revenue over the past 18 months.More than 50 global companies are actively relying on the platform, including General Motors, General Electric Vernova, Leonardo Aerospace, Eaton, Safran, Renault Group and multiple Formula 1 teams. Neural Concept, a global AI platform and leader in Engineering Intelligence powering next-generation product development, today announced it raised a $100 million Series C funding round led by Growth Equity at Goldman Sachs Alternatives, with existing investors Forestay Capital, Alven, HTGF, D.E. Shaw Ventures and Aster Capital. This press
Croma-Pharma Introduces New Medical Device for the Preparation of Autologous PRP | Fluid- PRF18.12.2025 16:57:00 CET | Press release
Croma-Pharma, a global player in minimally invasive aesthetic medicine, proudly announces the launch of its new medical device that is used for the preparation of autologous Platelet-Rich Plasma (PRP) | Fluid-Platelet-Rich Fibrin (Fluid-PRF).1 This launch represents continued progress in Croma’s mission to provide healthcare professionals state-of-the-art tools for their practice. With its innovative design and optimized separation technology, Exprecell™ enables the efficient preparation of autologous blood concentrates, without the use of anticoagulants, resulting in the formation of Fluid-PRF, a biologically active concentrate that retains the regenerative properties of platelets and leukocytes, yet stays liquid for a defined period.1 What makes Exprecell™ special?MDR certification: Exprecell™ is MDR-certified, meeting stringent EU regulatory requirements to ensure the safe, controlled and standardized preparation of autologous Platelet-Rich Plasma (PRP) | Fluid-Platelet-Rich Fibrin
In our pressroom you can read all our latest releases, find our press contacts, images, documents and other relevant information about us.
Visit our pressroom
